Clinical trials: Pneumococcal Vaccine
Pneumococcal Infections
Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization
This study is designed to assess the impact of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) on nasopharyngeal colonization with Streptococcus pneumoniae in healthy infants.
- Trial name
- NCT00508742
- Testing
- 13-valent Pneumococcal Conjugate Vaccine, 7 valent pneumococcal conjugate vaccine
- Where
- 5 sites in Israel
- Volunteers
- 1,866 people, healthy volunteers welcome
- Sponsor
- Pfizer
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.
The purpose of this study is to evaluate the immunogenicity and safety of 13-valent pneumococcal polysaccharide vaccine when given concomitantly with seasonal inactivated influenza vaccine to adults 50 years and older who have…
- Trial name
- NCT02124161
- Testing
- 13-valent pneumococcal conjugate vaccine, Seasonal Inactivated Influenza Vaccine
- Where
- 44 sites in United States
- Volunteers
- 882 people, healthy volunteers welcome
- Sponsor
- Pfizer
Infections, Streptococcal
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine
The purpose of this phase IIIb study is to determine whether children who have not received a 3-dose primary vaccination with the pneumococcal conjugate vaccine before their 6 months of age, can receive the vaccine as part of a…
- Trial name
- NCT00345358
- Testing
- Synflorix, Infanrix IPV/Hib
- Where
- 10 sites in Finland
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acute Otitis Media, Mastoiditis
Impact of Prevnar 13 on Ear Infections in Children
Prevnar (7 valent pneumococcal conjugate vaccine [7vPnC]) has been shown to be effective against ear infections in children. Prevnar 13 is a new vaccine that is similar to Prevnar.
- Trial name
- NCT01272999
- Testing
- No intervention
- Where
- 8 sites in United States
- Volunteers
- 391 people
- Sponsor
- Pfizer
Pneumococcal Infections
Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
The purpose of this study is to assess the safety, tolerability, and immunogenicity of a single dose of different formulations of V114 (V114-A and V114-B) and Prevnar 13® (pneumococcal 13-valent conjugate vaccine) in adult…
- Trial name
- NCT02547649
- Testing
- V114-A, V114-B, Prevnar 13®
- Volunteers
- 690 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Infections
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)
This study was designed to evaluate the safety and tolerability of a single dose of V114 when administered concomitantly and non-concomitantly (i.e., 30 days after) with influenza vaccine.
- Trial name
- NCT03615482
- Testing
- V114, QIV
- Where
- 45 sites in United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Vaccines, Pneumococcal Conjugate Vaccine
Post-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent)
To collect post-marketing information on the safety of Prevenar in Filipino patients
- Trial name
- NCT00683410
- Testing
- Pneumococcal Conjugate Vaccine, 7-valent (Prevenar)
- Where
- Philippines
- Volunteers
- 3,366 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumococcal Disease
Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination
This Phase 3 will describe the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine formulation in adults 65 years of age or older with prior pneumococcal vaccination
- Trial name
- NCT03835975
- Testing
- 13vPnC, PPSV23, 20vPnC
- Where
- 42 sites in United States, Sweden
- Volunteers
- 875 people, healthy volunteers welcome
- Sponsor
- Pfizer
Otitis Media
Effect of Prevnar 13 on Ear Infections in Children
Prevnar (7 valent pneumococcal conjugate vaccine [7vPnC]) has been shown to be effective against ear infections in children. Prevnar 13 is a new vaccine that is similar to Prevnar.
- Trial name
- NCT01199016
- Testing
- Tympanocentesis, Nose/throat swab, Observational
- Where
- 7 sites in United States
- Volunteers
- 239 people
- Sponsor
- Pfizer
Influenza, Infections, Pneumococcal
System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts
The goal of this research study is to improve rates of appropriate influenza and pneumococcal vaccination among adults who receive care at a large multi-specialty group practice in central Massachusetts.
- Trial name
- NCT02266277
- Testing
- Arm 1: E-portal message with IVR call, Arm 2: E-portal message with no IVR call, Arm 3: No e-portal message with IVR call
- Where
- United States
- Volunteers
- 30,000 people
- Sponsor
- University of Massachusetts, Worcester
Hepatitis A
Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age
This is a study to evaluate the immunogenicity and safety of GSK Biologicals 2-dose inactivated hepatitis A vaccine when administered with a pneumococcal conjugate vaccine in children as young as 15 months of age.
- Trial name
- NCT00197002
- Testing
- GSK Biologicals 2-dose inactivated hepatitis A vaccine (Havrix), Prevnar™
- Where
- 18 sites in United States
- Volunteers
- 521 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Neisseria Meningitidis, Haemophilus Influenzae Type b
Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines
This protocol posting deals with objectives \& outcome measures of an extension phase when subjects are aged 3, 4 and 6 years of age.
- Trial name
- NCT00891176
- Testing
- MenitorixTM, Pneumococcal conjugate vaccine GSK1024850A, PrevenarTM
- Where
- 28 sites in Germany, Poland and 1 more
- Volunteers
- 582 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Disease, 13-valent Pneumococcal Vaccine
Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.
This study is to evaluate the safety, immunogenicity and impact of 13-valent Pneumococcal conjugate vaccine in Alaskan Native Children.
- Trial name
- NCT00743652
- Testing
- 13-valent Pneumococcal Conjugate Vaccine
- Where
- 21 sites in United States
- Volunteers
- 373 people, healthy volunteers welcome
- Sponsor
- Pfizer
Infections, Meningococcal
Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration
The purpose of this study is to demonstrate, in 12-23 months old subjects, the non-inferiority of meningococcal vaccine GSK134612 and pneumococcal vaccine GSK1024850A when co-administered, compared to each vaccine administered…
- Trial name
- NCT00758264
- Testing
- Meningococcal vaccine GSK134612, Pneumococcal vaccine GSK1024850A
- Where
- 5 sites in Mexico, Taiwan
- Volunteers
- 363 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Bacterial Infections, Virus Diseases
A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)
This study will determine whether three manufacturing lots of V419 (PR5I) induce similar immune responses to all of the antigens contained in V419 when given concomitantly with Prevnar13™ and RotaTeq™.
- Trial name
- NCT01340937
- Testing
- V419, PENTACEL™, Prevnar 13™
- Volunteers
- 2,808 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumonia, Pneumococcal
Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants
The primary objectives of this study are to evaluate the immunogenicity (antibody response) and safety and tolerability of a 2-dose primary series and booster dose (2+1 schedule) of Pneumosil co-administered with routine…
- Trial name
- NCT03896477
- Testing
- Pneumosil, Prevenar 13, Synflorix
- Where
- The Gambia
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- PATH
Pneumococcal Infection
A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of V116 compared to PPSV23 in children and teenagers 2 through 17 years of age, who had completed routine pneumococcal vaccine as…
- Trial name
- STRIDE-13 (NCT06177912)
- Testing
- V116, PPSV23
- Where
- 92 sites in United States, Canada and 11 more
- Volunteers
- 882 people
- Sponsor
- Merck Sharp & Dohme LLC
Vaccines, Pneumococcal Conjugate Vaccine
Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC), relative to a 7-valent pneumococcal conjugate vaccine (7vPnC) when given concomitantly…
- Trial name
- NCT00688870
- Testing
- 13-valent pneumococcal conjugate vaccine (13vPnC), 7-valent pneumococcal conjugate vaccine (7vPnC)
- Where
- 2 sites in Taiwan
- Volunteers
- 168 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
HIV Infections, Streptococcus Pneumoniae
Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting
Purpose: To study the immune response of the newly licensed pneumococcal conjugate vaccine (PCV) in comparison to the pneumococcal polysaccharide vaccine (PPV) to determine if a significantly better immunologic response to…
- Trial name
- NCT00622843
- Testing
- pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine
- Where
- 6 sites in United States
- Volunteers
- 275 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Influenza
Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older
The purpose of this study is to investigate the immunogenicity and safety when GSK Biologicals' influenza vaccine Influsplit™ Tetra (Fluarix™ Tetra) is co-administered with Merck \& Co.
- Trial name
- NCT02218697
- Testing
- Influsplit™ Tetra (Fluarix™ Tetra), Pneumovax™ 23
- Where
- 6 sites in Belgium, France
- Volunteers
- 357 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline